<< Back
Halozyme Announces Issuance of U.S. Patent for rHuPH20 Enzyme Platform

Patent claims extend protection of enzyme and pharmaceutical compositions -

SAN DIEGO, Aug 12, 2010 /PRNewswire via COMTEX/ --Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced the issuance of U.S. Patent No. 7,767,429 claiming its proprietary recombinant human hyaluronidase enzyme platform (rHuPH20). Claims to the human PH20 glycoprotein, PEGylated variants, the glycoprotein produced by recombinant methods, and pharmaceutical compositions with other agents, including antibodies, insulins, cytokines, anti-infectives and additional therapeutic classes were awarded in the '429 patent. Additional claims are in prosecution.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100302/LA63139LOGO)

In the U.S., the issued patent would expire in March 5, 2024, but the term will be extended until September 23, 2027 with the addition of patent term adjustment time of 1,297 days. A broad European counterpart, EP1603541, has also been granted to Halozyme that will provide protection until March 5, 2024. To date, similar claims have been granted in India, Japan, Eurasia, Hong Kong, Mexico, New Zealand, Singapore and South Africa.

"We are pleased to receive recognition for these biotechnology innovations," stated Gregory Frost, Ph.D., Halozyme's chief scientific officer. "These foundational patents, and the protection provided, are of significant value to Halozyme and to its development partners, and cover major pharmaceutical markets of the world."

The claims for the newly issued U.S. patent cover compositions of matter and pharmaceutical compositions for rHuPH20 including:

  • The purified hyaluronidase glycoprotein
  • Chemically modified forms of the hyaluronidase glycoprotein, including PEGylated variants
  • Compositions comprising the recombinant hyaluronidase glycoprotein in product-by-process format
  • Pharmaceutical compositions comprising the hyaluronidase glycoprotein and pharmaceutically active agents, including biologics, peptides and small molecules

Additional information about these patents may be found on the U.S. Patent and Trademark Office and on the European Patent Office Web sites.

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze(TM) technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze technology to Roche's biological therapeutics, including Herceptin(R) and MabThera(R), for up to 13 targets, and with Baxter BioScience to apply Enhanze technology to GAMMAGARD Liquid(R). Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit http://www.halozyme.com/.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the benefits and protection of issued patents) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

    Halozyme Contact
    Robert H. Uhl
    Senior Director, Investor Relations
    (858) 704-8264
    ruhl@halozyme.com


SOURCE Halozyme Therapeutics, Inc.

Could not find file '\\aws.nasdaqomx.com\irwebpro\content3\IRXMLDATA\17\175436\Disclaimers.xml'.